Trial Profile
Clinical evaluation for the efficacy, safety, tolerability and medical resource utilization of Invanz (ertapenem sodium) therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2017
Price :
$35
*
At a glance
- Drugs Ertapenem (Primary)
- Indications Bacterial infections
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 01 Feb 2007 Status changed from recruiting.
- 25 Nov 2006 New trial record.